4,168 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Purchased by Xponance Inc.

Xponance Inc. purchased a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,168 shares of the company’s stock, valued at approximately $233,000.

Several other large investors have also recently added to or reduced their stakes in the company. SRS Capital Advisors Inc. boosted its position in shares of Rhythm Pharmaceuticals by 740.7% during the 4th quarter. SRS Capital Advisors Inc. now owns 454 shares of the company’s stock valued at $25,000 after acquiring an additional 400 shares in the last quarter. Raleigh Capital Management Inc. bought a new position in Rhythm Pharmaceuticals during the fourth quarter worth about $28,000. SBI Securities Co. Ltd. acquired a new stake in Rhythm Pharmaceuticals during the fourth quarter valued at approximately $37,000. R Squared Ltd bought a new stake in shares of Rhythm Pharmaceuticals in the 4th quarter valued at approximately $44,000. Finally, KBC Group NV raised its holdings in shares of Rhythm Pharmaceuticals by 78.2% in the 4th quarter. KBC Group NV now owns 2,251 shares of the company’s stock worth $126,000 after buying an additional 988 shares in the last quarter.

Rhythm Pharmaceuticals Price Performance

Shares of Rhythm Pharmaceuticals stock opened at $54.80 on Friday. The firm has a market cap of $3.46 billion, a price-to-earnings ratio of -12.66 and a beta of 2.30. The stock’s 50-day moving average is $55.25 and its 200-day moving average is $55.03. Rhythm Pharmaceuticals, Inc. has a one year low of $35.17 and a one year high of $68.58.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The business had revenue of $41.83 million during the quarter, compared to analyst estimates of $38.48 million. On average, equities analysts expect that Rhythm Pharmaceuticals, Inc. will post -4.32 EPS for the current year.

Insider Activity at Rhythm Pharmaceuticals

In other news, insider Joseph Shulman sold 1,281 shares of Rhythm Pharmaceuticals stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $59.43, for a total value of $76,129.83. Following the completion of the transaction, the insider now owns 2,657 shares of the company’s stock, valued at $157,905.51. This trade represents a 32.53 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Christopher Paul German sold 635 shares of the company’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total transaction of $36,334.70. Following the completion of the sale, the chief accounting officer now directly owns 2,070 shares in the company, valued at approximately $118,445.40. The trade was a 23.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 108,131 shares of company stock valued at $5,781,098. 5.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

RYTM has been the topic of several recent analyst reports. JMP Securities reissued a “market outperform” rating and issued a $75.00 target price on shares of Rhythm Pharmaceuticals in a report on Monday, December 23rd. Oppenheimer assumed coverage on Rhythm Pharmaceuticals in a report on Friday, December 20th. They set an “outperform” rating and a $76.00 target price on the stock. Jefferies Financial Group initiated coverage on Rhythm Pharmaceuticals in a report on Thursday, January 2nd. They issued a “buy” rating and a $80.00 price target for the company. Stifel Nicolaus assumed coverage on shares of Rhythm Pharmaceuticals in a research report on Wednesday, March 5th. They set a “buy” rating and a $78.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Monday, March 24th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $69.46.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.